[Research Articles] Plasmodium falciparum Pf77 and male development gene 1 as vaccine antigens that induce potent transmission-reducing antibodies
Malaria vaccines that disrupt the Plasmodium life cycle in mosquitoes and reduce parasite transmission in endemic areas are termed transmission-blocking vaccines (TBVs). Despite decades of research, there are only a few Plasmodium falciparum antigens that indisputably and reproducibly demonstrate transmission-blocking immunity. So far, only two TBV candidates have advanced to phase 1/2 clinical testing with limited success. By applying an unbiased transcriptomics-based approach, we have identified Pf77 and male development gene 1 (PfMDV-1) as two P. falciparum TBV antigens that, upon immunization, induced antibodies that caused reductions in oocyst counts in Anopheles mosquito midguts in a standard membrane feeding assay. In-depth studies were performed to characterize the genetic diversity of, stage-specific expression by, and natural immunity to these two molecules to evaluate their suitability as TBV candidates. Pf77 and PfMDV-1 display limited antigenic polymorphism, are pan-developmentally expressed within the parasite, and induce naturally occurring antibodies in Ghanaian adults, which raises the prospect of natural boosting of vaccine-induced immune response in endemic regions. Together, these biological properties suggest that Pf77 and PfMDV-1 may warrant further investigation as TBV candidates.
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tripathi, A. K., Oakley, M. S., Verma, N., Mlambo, G., Zheng, H., Meredith, S. M., Essuman, E., Puri, A., Skelton, R. A., Takeda, K., Majam, V., Quakyi, I. A., Locke, E., Morin, M., Miura, K., Long, C. A., Kumar, S. Tags: Research Articles Source Type: research
More News: Biomedical Science | Endemics | Genetics | Ghana Health | Malaria | Malaria Vaccine | Parasitic Diseases | Parasitology | Science | Study | Vaccines